Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation
about
Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinomaNeoadjuvant therapy for localized pancreatic cancer: guiding principlesNeoadjuvant therapy for pancreas cancer: past lessons and future therapiesBiomarkers in pancreatic adenocarcinoma: current perspectivesGemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response.Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy.Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 exprSerum carcinoembryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: A meta-analysis.Metastatic recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) nude mouse model is inhibited by neoadjuvant chemotherapy in combination with fluorescence-guided surgery with an anti-CA 19-9-conjugated fluorophore.CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma.Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.Current status of adjuvant therapy for pancreatic cancer.Fluorescence-guided surgery, but not bright-light surgery, prevents local recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) model resistant to neoadjuvant chemotherapy (NAC)Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancerPreoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinomaPancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic ManagementThe Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of PancreasClinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma.Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.Key factors influencing prognosis in relation to gallbladder cancer.Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.Pancreas club international joint symposium on pancreatic cancer 2012, Kyoto: down staging chemo±radiotherapy for borderline resectable pancreatic cancer.Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult.Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy.Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.Tumor heterogeneity of pancreas head cancer assessed by CT texture analysis: association with survival outcomes after curative resection.
P2860
Q26739910-42AEF604-38C5-49DF-8B4A-A93748A4E9E7Q26799428-20838E2F-D0EE-4459-BA74-DB27D91AC5CCQ27004292-C91FCBBF-D29A-4F71-9379-4C36D8DA38E9Q28072309-5758479B-B118-4CD5-A27D-B4C4FA1E6EF2Q33443909-110F1181-097C-40DD-A592-AA72D3EB5117Q33558951-4ABFC48D-8D83-42F2-853B-BA3D4A0EC1AFQ33665450-E1648DE4-1CFF-4738-8905-519CE66E9EECQ33956574-5726F971-DD4D-4B31-AB97-4BEC3B2146D3Q34275247-58C20A76-F228-4EC3-AB50-ED7C2696C90AQ34408283-7B7D7667-7902-41BD-9AB6-6193230EAD7FQ34607328-08190D79-16CD-46B3-846E-97333A51735DQ34612412-909F13BC-9448-410C-9AE2-4B779F0DB445Q34646563-CF34D347-5B83-4F75-B1E9-3DCAAE9791BDQ34680864-F229F9F5-E1F0-4DF8-88AB-2698B29BB328Q35059969-37440238-2411-4A02-AD2F-6D9E1E1E1D84Q35583760-5074EB94-F7F7-4D5E-8774-7B960B92D521Q35655968-28962242-A8DD-4719-9061-F639EC0105B3Q36064780-4AF8D5C6-BFEA-47B0-8BE1-6560C49C11C9Q36151583-E61A1111-4F51-4200-887E-0F0092754A46Q36281575-AC7B1E50-2DEC-4552-BC54-E8F64763545DQ36831137-7494F5AD-548F-4586-997A-4FB0F6C1E595Q36853409-99F21AD6-5DCC-4B85-9609-1BE178A16C70Q38018315-D8775E51-4C93-47D3-8B36-364A55F0ACCAQ38108546-5B086D37-464A-4D8D-9975-F3114606B352Q38261491-8D969164-685F-4FAA-82C5-5250C7EECC5CQ39010876-BA60B33B-3286-41C8-B6F8-5E26AA6302ABQ39023169-C5656014-677D-4D52-B2E2-E64381817250Q39148761-E2A8B614-8885-42EF-9EA2-032637A86E98Q39371358-9D66504A-3381-4CE4-9F4A-52C6D2BBBA68Q40758068-7F2BA12B-CC89-4835-96E0-21BA95229940Q41573034-2396ACCE-69D3-4D1A-A467-66915FC5B788Q42238114-39CE6922-4E6C-4E82-9996-EC3F0E06E183Q42374126-0ABDEF8B-BD66-4A37-A51E-197FCB269457Q42947960-55807923-2F46-4095-BEB4-1688FE76B5DDQ45846973-B8DE382E-6802-4662-970B-36EE378C115DQ51442653-666EEC6C-0AF6-4E87-96D5-44737E0A2403Q51751748-42356900-E5B1-4978-8EEA-638C7EF364B2Q55069065-E978C278-E8B3-490D-B149-0094826ACD48
P2860
Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Serum CA 19-9 as a marker of r ...... ith neoadjuvant chemoradiation
@ast
Serum CA 19-9 as a marker of r ...... ith neoadjuvant chemoradiation
@en
type
label
Serum CA 19-9 as a marker of r ...... ith neoadjuvant chemoradiation
@ast
Serum CA 19-9 as a marker of r ...... ith neoadjuvant chemoradiation
@en
prefLabel
Serum CA 19-9 as a marker of r ...... ith neoadjuvant chemoradiation
@ast
Serum CA 19-9 as a marker of r ...... ith neoadjuvant chemoradiation
@en
P2093
P2860
P1476
Serum CA 19-9 as a marker of r ...... ith neoadjuvant chemoradiation
@en
P2093
Charlotte C Sun
Christopher H Crane
Douglas B Evans
Eddie K Abdalla
Eric P Tamm
Gauri R Varadhachary
Huamin Wang
James L Abbruzzese
Jason B Fleming
Jeffrey E Lee
P2860
P2888
P304
P356
10.1245/S10434-010-0943-1
P577
2010-02-17T00:00:00Z
P5875
P6179
1029391075